Navigation Links
Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
Date:5/15/2008

BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will apply its proprietary lentiviral vector (LV) technology to the development of novel immunotherapeutic treatments for diseases of high unmet medical need:

-- Melanoma, with Michael Nishimura, Ph.D, Associate Professor of Surgery,

Medical University of South Carolina

-- Hepatitis C virus (HCV) infection, also with Dr. Nishimura

-- Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner,

M.D./Ph.D., Principal Investigator, National Cancer Institute

-- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner

Together with its collaborators, Lentigen will develop lentiviral vectors designed to target specific cells related to each of these diseases. For melanoma, HCV, and EBV, the vectors will transduce T cells, which play a central role in cell-mediated immunity, with proteins known as T cell receptors (TCRs) that have been engineered to attack the targeted disease. For CLL, the vectors will carry weakened cells of this cancer combined with other substances designed to trigger an immune response.

"These innovation research grants are enabling us to extend the application of our lentiviral vector technology to a wider range of diseases while working with distinguished researchers to address the urgent need for novel biotherapeutics and vaccines in areas of high unmet medical need," said Tim Ravenscroft, Lentigen's CEO.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the deli
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
2. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VIRxSYS and Lentigen Announce Litigation Settlement
6. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
7. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
9. Genaera Corporation Announces First Quarter Financial Results
10. EUSA Pharma Completes Acquisition Of Cytogen Corporation
11. Pharmos Corporation Reports 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... , March 3, 2015 ... with tools for implementing competency-based training to comply with ... DirectCourse is offering a new crosswalk tool ... (HCBS) implement competency-based training for direct service workers as ... & Medicaid Services (CMS) regulations. CMS amended ...
(Date:3/3/2015)... Md. , March 3, 2015  Synthetic Biologics, Inc. ... infections and diseases, with a focus on protecting the microbiome, ... is scheduled to present at the 27th Annual ROTH Conference ... Laguna Niguel in Dana Point, ... Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). ...
(Date:3/3/2015)... 3, 2015  PDL BioPharma, Inc. (PDL or the ... the third of three shareholder lawsuits filed in the ... On February 2, 2015, a securities lawsuit that ... of a putative class of purchasers of the Company,s ... 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without prejudice.  Shortly ...
Breaking Biology Technology:Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2
... Quintiles,Transnational Corp. today announced the appointment of ... Troullis had been,acting CFO since former CFO John ... Troullis joined Quintiles in 1992 as Director ... CFO, Troullis was Senior Vice President and,Worldwide Controller. ...
... Offer Regulatory ... Operations Expertise, WHIPPANY, N.J., Aug. ... services to streamline the drug,development lifecycle, today announced the expansion of ... Diego. The announcements,illustrate the company,s newly elevated focus on emerging West ...
... at the 58th Annual Meeting of ... (AASLD), TAMPA, Fla., Aug. 15 Romark Laboratories ... of Alinia(R) (nitazoxanide) for,treating chronic hepatitis C in the ... evaluate the effectiveness and safety,of Alinia tablets administered in ...
Cached Biology Technology:ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 2ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 3ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego 4Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 2Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 3Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States 4
(Date:2/5/2015)... Conn. , Jan. 28, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... at the upcoming RedChip Global Online CEO Conference on ... Gino Pereira , CEO of NXT-ID ... its lead product, the Wocket smart wallet and its ...
(Date:2/5/2015)... JOLLA, Calif. , Jan. 30, 2015  It ... the great power and potential for genomic science as ... aid in disease prevention and treatment.  I was honored ... potential new, government-funded precision medicine program. ... advancing the science of genomics—from the first sequenced genome ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... North Carolina State University researcher has shown that water-gel-based ... solar cells to produce electricity. The findings prove the ... nature. They also have the potential to be less ... silicon-based solar cells. The bendable devices are composed ...
... , This release is available in Spanish ... a popular native Hawaiian fruit, has been released by U.S. ... cooperators. ,Ōhelo ( Vaccinium reticulatum Smith ) is ... found at high elevations on the islands of Maui and ...
... an effective vaccine for malaria is a step closer following ... to infect human cells. The discovery, by researchers at The ... new vaccine target through which infection with the deadly disease ... people contract malaria, and more than one million, mostly children, ...
Cached Biology News:Mimicking nature, water-based 'artificial leaf' produces electricity 2Scientists release first cultivated ohelo berry for Hawaii 2Malaria's newest pathway into human cells identified 2
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
BACE (CT) rabbit polyclonal antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Biology Products: